Zimmer Biomet has achieved a perfect 4-for-4 earnings beat streak and a maximum Piotroski F-Score of 9/9, yet trades at a death-cross technical setup with almost no gap to its analyst price target, making the risk-reward unattractive at current levels.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Maximum Piotroski Quality Score→Stable
- Analyst Target Exhausted↑Improving
- +1 more pillar — see the Why tab for full reasoning
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $90.07, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source materials and components; Thin upside margin: 7.5%.
Zimmer Biomet designs, manufactures and markets orthopedic implants (knees, hips), sports medicine/biologics/trauma products, craniomaxillofacial devices, and digital/robotic technologies across Americas, EMEA and Asia Pacific segments. Approximately 85% of 2025 net sales were... Read more
Hold if already holding. Not a fresh buy at $90.07, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source materials and components; Thin upside margin: 7.5%. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 41d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-09-25Recent Developments — Zimmer Biomet Holdings, Inc.
Latest news
- NEWS Zimmer Biomet (ZBH) Is Up 7.7% After Q1 Beat And Confident Outlook Commentary - What's Changed - finance.yahoo.com — finance.yahoo.com positive
- NEWS Zimmer Biomet (ZBH) Is Up 7.7% After Q1 Beat And Confident Outlook Commentary - What's Changed - Yahoo Finance — Yahoo Finance positive
- NEWS Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? - TradingView — TradingView neutral
- NEWS Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? - finance.yahoo.com — finance.yahoo.com neutral
- NEWS Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? - tradingview.com — tradingview.com neutral
Generated 2026-09-25T23:46:59Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle-source materials and components10-K Item 1A: 'Certain of these materials and components and outsourced activities can only be obtained from a single source or a limited number of sources due to quality considerations'
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02MEDIUMCFO Suketu Upadhyay resigned effective April 28, 2026 to pursue a new professional opportunity; no disagreement with the company cited. Paul Stellato (VP, Controller and CAO) appointed interim CFO; permanent search underway.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $90.07, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source materials and components; Thin upside margin: 7.5%. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $96.81 (+7.5%), stop $86.35 (−4.3%), A.R:R 1.1:1. Score 6.0/10, moderate confidence.
Take-profit target: $96.81 (+7.5% upside). Target $96.81 (+7.5%), stop $86.35 (−4.3%), A.R:R 1.1:1. Stop-loss: $86.35.
Concentration risk — Supplier: single-source materials and components; Thin upside margin: 7.5%; Negative momentum.
Zimmer Biomet Holdings, Inc. trades at a P/E of 21.8 (forward 9.9). TrendMatrix value score: 7.8/10. Verdict: Hold.
33 analysts cover ZBH with a consensus score of 3.4/5. Average price target: $108.
What does Zimmer Biomet Holdings, Inc. do?Zimmer Biomet designs, manufactures and markets orthopedic implants (knees, hips), sports medicine/biologics/trauma...
Zimmer Biomet designs, manufactures and markets orthopedic implants (knees, hips), sports medicine/biologics/trauma products, craniomaxillofacial devices, and digital/robotic technologies across Americas, EMEA and Asia Pacific segments. Approximately 85% of 2025 net sales were consignment-based; no single customer exceeded 2% of net sales. The company employed approximately 17,000 people worldwide as of December 31, 2025.